Jennifer J. Rhodes

GC & Chief Compliance Officer, Medivation.

Companies

Acadia PharmaceuticalsGeneral counsel Feb 8, 2024 to now¹
Elicio Therapeutics, Inc.Officer Feb 4, 2021 to Mar 4, 2022²
Adamas Pharmaceuticals (United States)CBO, GC & Compliance Officer Jan 20, 2017 to Jun 21, 2019³
Adamas Pharmaceuticals (United States)General counsel Apr 14, 2016 to Nov 8, 2016⁴
MedivationGC & Chief Compliance Officer Mar 29, 2013 to Mar 17, 2015⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Acadia Pharmaceuticals ACAD11,280 shares⁶$221.2K at $19.61Mar 25, 2026
Elicio Therapeutics, Inc. ELTX30,399 shares⁷$46.2K at $1.52Dec 14, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 25, 2026Sold 3,844 shares at $21.47 of Acadia Pharmaceuticals⁶
Mar 24, 2026Exercised options 7,515 shares of Acadia Pharmaceuticals⁶
Feb 9, 2026Sold 6,950 shares at $23.38 of Acadia Pharmaceuticals⁸
Feb 6, 2026Exercised options 12,944 shares of Acadia Pharmaceuticals⁸
Dec 14, 2021Sold 451 shares at $2.42 of Elicio Therapeutics, Inc.⁷
Nov 15, 2021Sold 433 shares at $4.40 of Elicio Therapeutics, Inc.⁹
Oct 14, 2021Sold 430 shares at $8.65 of Elicio Therapeutics, Inc.¹⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAcadia Pharmaceuticals, General counsel
2
SEC EDGARElicio Therapeutics, Inc., Officer
3
SEC EDGARAdamas Pharmaceuticals (United States), CBO, GC & Compliance Officer
4
SEC EDGARAdamas Pharmaceuticals (United States), General counsel
5
SEC EDGARMedivation, GC & Chief Compliance Officer
6
SEC EDGARAcadia Pharmaceuticals shares after the filing of Mar 25, 2026
7
SEC EDGARElicio Therapeutics, Inc. shares after the filing of Dec 14, 2021
8
SEC EDGARForm 4 filed Feb 10, 2026
9
SEC EDGARForm 4 filed Nov 16, 2021
10
SEC EDGARForm 4 filed Oct 15, 2021